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Abstract The number of dihydropyridine receptors (DHPR) 
and sarcoplasmic reticulum (SR) Ca2+ release channels (RyRl) 
and their interaction determine the efficacy of the sarcolemmal 
excitation-SR Ca2+ release-contraction coupling (ECC). Both 
receptors play a central role in ECC as demonstrated in various 
animal species and muscle subtypes. In the present work we 
studied the effect of transgenic overexpression of human insulin-
like growth factor 1 (hIGF-1) on the levels of these two Ca2+ 
channels in extensor digitorum longus (EDL) (fast-twitch), soleus 
(slow-twitch) and pool of fast- and slow-twitch muscles from 
adult C57BL/6 mice. Muscles from hIGF-1 transgenic mice 
showed a significant increase in IGF-1 concentration (20-30-
fold) and in the number of DHPR (52% increase) whereas no 
significant change in RyRl binding sites was detected. The 
differential effect on DHPR and RyRl resulted in a 30% 
increase in DHPR/RyRl ratio. Fast- and slow-twitch muscles 
showed 50 and 70% increase in the number of DHPR and 30 and 
80% increase in DHPR/RyRl, respectively. These results 
support the concept that the increased autocrine/paracrine 
secretion of hIGF-1 exerts potent stimulatory effects on DHPR 
a l subunit expression in adult skeletal muscle. 
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muscles [5] which may explain, at least partially, the decline in 
muscle force with aging [6]. Despite the established fast mod-
ulation of voltage-sensitive Ca2+ channels by IGF-1, long-
term effects of sustained high levels of the trophic factor in 
skeletal muscle on DHPR and RyRl are unknown. 
In the present study we explored the effects of exclusive 
overexpression of IGF-1 on skeletal muscle DHPR and 
RYR1 in transgenic S1S2 mice [7]. In this animal model the 
role of auto/paracrine secretion of IGF-1 in muscle proteins 
can be investigated separately from the endocrine influence. 
S1S2 mice exhibit pronounced muscle hypertrophy without 
increases in overall body weight or circulating IGF-1 concen-
tration [7]. Because specific muscle force declines with age in 
several animal species and in humans [8-10] mechanisms of 
muscle weakness not associated with muscle mass have been 
explored. Among these mechanisms, age-related alterations in 
muscle DHPR-RyRl coupling have been demonstrated in hu-
mans and rodents [11] [12]. 
We hypothesize that age-dependent DHPR-RyRl uncou-
pling and the associated decline in muscle strength can be 
prevented or delayed by IGF-1-mediated increase in DHPR 
expression. Therefore, in this study we investigated whether 
high autocrine/paracrine IGF-1 secretion is associated with 
higher levels of DHPR ocl subunit and RyRl in adult fast-
and slow-twitch muscles and muscles consisting of fast and 
slow fibers from S1S2 transgenic and wild-type FVB mice. 
1. Introduction 
Intracellular Ca2+ release in response to the dihydropyri-
dine receptor (DHPR) a l subunit activation is a key process 
that modulates skeletal muscle contraction. Studies in various 
animal species and muscle subtypes demonstrated that the 
absolute number of DHPR and sarcoplasmic reticulum (SR) 
Ca2+ release channels (RyRl) and their interaction determine 
the properties of excitation-contraction coupling [1,2]. There-
fore, the modulation of DHPR and RyRl expression and 
function may have significant impact on muscle contraction 
force and kinetics. 
Insulin-like growth factor 1 (IGF-1) induces skeletal muscle 
proliferation, differentiation and expression of multiple genes 
[3]. We have demonstrated that in addition to effects on 
muscle development, IGF-1 facilitates skeletal muscle 
DHPR activity via tyrosine kinase-PKC-dependent phospho-
rylation [4]. Our laboratory has also communicated that IGF-
1-dependent DHPR modulation is impaired in aging skeletal 
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2. Materials and methods 
2.1. S1S2 hIGF-1 transgenic and FVB non-transgenic mice 
S1S2 transgenic mice overexpressing human IGF-1 (hIGF-1) exclu-
sively in skeletal muscle and control wild-type FVB mice (12 months 
old) were used. Animals were housed in a pathogen-free area at Bow-
man Gray School of Medicine (BGSM) and fed ad libitum. S1S2 mice 
were screened for the presence of hIGF-1 genomic DNA to identify 
transgenic from wild-type mice (see below). Animal procedures fol-
lowed an approved protocol by the Animal Care and Use Committee 
of BGSM. 
2.2. Screening for human IGF-1 (hIGF-1) genomic DNA 
Mouse tail segments were excised and digested overnight at 55°C in 
digestion buffer containing 1 M Tris-NaOH, pH 8.0, 5 M NaCl, 0.5 
M ethylenediamine-tetraacetic acid, 20% sodium dodecyl sulfate and 
20 mg/ml proteinase K. From this mixture, DNA was extracted by 
phenol:chloroform:isoamyl alcohol (25:24:1). Human IGF-1 gene 
was screened from this DNA by polymerase chain reaction (PCR) 
with specific 25-base primers: hIGF-1 5': ATT TAA gTg Ctg CTT 
Ttg TgA TTT C and hIGF-1 3' TTC CTA CAT CCT gTA gTT CTT 
gTT T. Amplified DNA fragments were analyzed for the presence of a 
clear 450-bp fragment specific for hIGF-1 on 2.5% agarose gels. 
2.3. Determination of IGF-1 concentration by radioimmunoassay 
Frozen quadriceps muscles were powdered under liquid N2 and 
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then homogenized (1:5 w/v) in 1 M acetic acid using a Polytron tissue 
homogenizer. Homogenate was incubated for 2 h to separate the 
debris from the supernatant. Homogenate equivalent to 100 ug pro-
tein was added to the reaction mixture containing 50 mM phosphate, 
pH 7.5, 50 mM NaCl, 10 mM EDTA, 3 mM sodium azide and 0.25% 
BSA. IGF-1 antiserum was a kind gift from NIDDK. The concen-
tration of antiserum required for the maximum detection of IGF-1 
was determined from IGF-1-antiserum titration. IGF-1 antiserum was 
specifically withheld in some reaction tubes to determine non-specific 
binding of radiolabeled IGF-1. Thr59IGF-l (Bachern, Inc., Torrence, 
CA) was radiolabeled with 125I using the lactoperoxidase, glucose 
oxidase procedure [13]. The optimal counts needed for maximal 
IGF-1 detection were determined by titrating radiolabeled IGF-1 
against known IGF-1 concentration. To initiate the reaction 50000 
counts per tube were added and incubated overnight at room temper-
ature. IGF-1-antiserum complex was precipitated by protein A for 30 
min and the precipitate was pelleted down by centrifuging at 3000 X g 
for 15 min. Radioactive IGF-1 in the pellet was estimated in a y-
counter. Data are expressed per mg of protein in relation to IGF-1 
standards. The minimum and maximum detectable doses were 15 and 
1000 pg IGF-1. 
2.4. Muscle homogenate and radioligand binding to DHPR and RyRl 
Extensor digitorum longus (EDL), soleus and whole leg muscles 
were studied. Muscles were homogenized as described [5]. Protein 
concentration was determined by Coomassie protein assay with bo-
vine serum albumin as the protein calibration standard. 
DHPR and RyRl concentrations were determined using the radio-
ligands [3H]PN200-110 and [3H]ryanodine, respectively. Homogenate 
(1-2 mg/ml protein) were incubated either with 0.05-5 nM 
[3H]PN200-110 for 1 h at 23°C in 50 mM Tris-HCl, pH 7.5, 10 iiM 
Ca2+, 1 mM diisopropyl fluorophosphate (DIFP) and 5 |xM leupeptin 
or 0.5-50 nM [3H]ryanodine for 24-48 h at 10°C in 20 mM PIPES-
NaOH, pH 7.0, 1.0 M NaCl, 100 |xM Ca2+, 5 mM AMP, 1 mM 
DIFP, and 5 iiM leupeptin. Membrane bound [3H]PN200-110 and 
[3H]ryanodine were determined by filtration through Whatman GF/ 
B filters using a Millipore unit (XX2702550, Millipore Corporation, 
Bedford, MA). Filters were rinsed three times with 5 ml of ice cold 
200 mM choline chloride, 20 mM Tris-HCl, pH 7.5. Non-specific 
[3H]PN200-110 and [3H]ryanodine binding was assessed in the pres-
ence of 10 uM unlabeled nifedipine (Sigma Chemical Company, St. 
Louis, MO) or PN200-110 (Sandoz Pharmaceutical, East Hanover, 
NJ) and 10 (iM unlabeled ryanodine (Calbiochem, San Diego, CA) 
respectively. Radioligand concentrations used resulted in occupancy 
of > 95% of the high-affinity binding sites [1]. 
2.5. Data analysis 
Linear regression and non-linear least squares analysis were used to 
calculate non-specific and total binding of the radioligands to the 
receptors. Specific binding of [3H]PN200-110 and [3H]ryanodine at 
each concentration was calculated by subtracting the non-specific 
binding from the total binding obtained from the above analysis. 
The following equation 
y= (xa)((x + b) + {xc)) (1) 
where a = receptor number (Bmax); b = Ko, dissociation constant; 
c = the non-specific binding or the low affinity site, was used to fit the 
binding isotherm. Data were also given in a graphical representation of 
the Scatchard plot. There was no significant difference in Smax values 
obtained from the curve fit or Scatchard plot [12]. All values were 
analyzed for statistical significance using unpaired Student's i-test. 
3. Results 
Two groups of five 12-month-old S1S2 transgenic and FVB 
non-transgenic mice were used in this study. The presence of 
hIGF-1 gene was detected by PCR analysis of genomic DNA. 
PCR was conducted using specific primers for hIGF-1 [7] (see 
Section 2). PCR fragments from the five transgenic and non-
transgenic mice were analyzed on 2.5% agarose gel. Trans-
genic mice showed a single DNA band of 450 bp indicating 
the presence of hIGF-1 in the genomic DNA (Fig. 1). 
The extent of hIGF-1 gene expression in S1S2 transgenic 
skeletal muscles was determined by measuring IGF-1 concen-
tration in quadriceps muscles (Table 1). The mean IGF-1 
concentration in non-transgenic and transgenic mice was 
825 ±268 and 21 870 ±5982 pg/mg total muscle protein, re-
spectively. The difference between both groups was statisti-
cally significant (P< 0.001). Skeletal muscles from transgenic 
mice exhibited a 20-30-fold higher concentration of IGF-1 
than non-transgenic mice. This increase is similar to that re-
ported for S1S2 hIGF-1 transgenic mice [7]. 
The concentration of DHPR and RyRl and their dissocia-
tion constant for high-affinity radioligands were determined in 
a pool of muscles consisting of both fast- and slow-twitch 
muscle fibers. DHPR and RyRl were quantitated in mouse 
skeletal muscle homogenates with the use of [3H]PN200-110 
and [3H]ryanodine. Fig. 2 shows the [3H]PN200-110 and 
[3H]ryanodine binding (mean ± S.D.) analysis of five transgen-
ic and five non-transgenic mice. The insets for both figures are 
the Scatchard analyses of ligand binding to the DHPR and 
RyRl, respectively. _Smax and KD values were determined by 
Scatchard analysis or by fitting Eq. 1 to binding data. 
Individual non-transgenic and transgenic [3H]PN200-110 
and [3H]ryanodine -ßmax, Ko, and DHPR/RyRl ratio values 
were calculated from Scatchard analyses of the binding assay 
and are given in Table 1. Bm&x and Ko values for transgenic 
muscles were (mean ± S.D.) 4.03 ±0.27 pmol/mg protein and 
1.4 ±1.03 nM, respectively and for non-transgenic muscles 
were 2.53 ±0.62 pmol/mg protein and 1.9 ±0.79 nM, respec-
tively. These results demonstrate that exclusive overexpression 
Table 1 
Mouse [IGF-1] 
Non-transgenic 
W 
ASE 
BQ 
BC 
BX 
Transgenic 
AO 
AG 
AP 
AQ 
BB 
-
1185 
725 
550 
840 
-
17290 
20165 
19380 
30660 
Pool 
DHPR 
-»max 
2.43 
2.96 
2.95 
1.48 
2.81 
3.80 
4.42 
4.06 
3.76 
4.09 
^ D 
1.25 
2.5 
1.69 
1.17 
2.97 
1.04 
0.40 
0.85 
2.08 
0.68 
RyRl 
"max 
2.49 
2.83 
2.89 
1.55 
3.14 
2.8 
3.2 
3.31 
3.32 
3.2 
Kv 
7.7 
11.4 
9.6 
16.9 
8.0 
7.3 
5.9 
3.3 
6.9 
7.6 
Ratio 
0.98 
1.05 
1.02 
0.95 
0.89 
1.36 
1.37 
1.24 
1.16 
1.28 
EDL 
DHPR 
5.98 
5.40 
9.45 
8.13 
6.13 
9.8 
8.2 
13.7 
11.0 
10.1 
RyRl 
"max 
6.1 
6.1 
8.5 
6.8 
6.1 
7.8 
6.1 
9.7 
7.9 
9.9 
Ratio 
0.99 
0.88 
1.12 
1.19 
1.01 
1.26 
1.34 
1.42 
1.39 
1.01 
Soleus 
DHPR 
Bmax 
2.23 
2.08 
3.03 
5.02 
2.82 
5.20 
5.80 
5.63 
3.98 
5.26 
RyRl 
Smax 
5.85 
5.80 
7.76 
6.40 
6.33 
6.78 
6.50 
8.92 
4.96 
5.68 
Ratio 
0.38 
0.36 
0.39 
0.78 
0.45 
0.77 
0.89 
0.63 
0.80 
0.93 
IGF-1 concentration is expressed in pg/mg protein. 2?max and Äjj are expressed in pmol/mg protein and nM, respectively. 
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Fig. 1. Screening for hIGF-1 genomic DNA in mouse skeletal muscle on 2.5% agarose gel. Lanes 1 and 12 depict DNA markers of 200-1000 
bp. Lanes 2-6 are non-transgenic mice labeled W, ASE, BQ, BC and BX. Lanes 7-11 are transgenic mice AO, AG, AP, AQ and BB. hIGF-1 
band is located at 450 bp. 
of IGF-1 in skeletal muscle is associated with a 52% increase 
in the number of DHPR od subunit (P = 0.001). Scatchard 
analysis of ryanodine binding assays gave a Bmllx of 
3.15 ±0.20 pmol/mg protein and a KD of 12.18 ±8.69 for 
transgenic muscles and Bmax of 2.58 ±0.62 pmol/mg protein 
and KD of 10.78 ±3.76 nM for non-transgenic muscles. The 
difference in [3H]ryanodine Bmax between transgenic and non-
transgenic muscles is not statistically significant (P = 0.086), 
which suggests that the ryanodine receptor gene expression 
is not susceptible to IGF-1 modulation. The DHPR/RyRl 
ratio, which is an indication of the proportion of receptors 
coupled [2] [1], has been included in Table 1. The PN200-110/ 
ryanodine (DHPR/RyRl) Bmax ratio of 0.98 ±0.07 (mean± 
S.D., 10 determinations from five different preparations) for 
non-transgenic FVB mice muscles is similar to that reported 
for matured rabbit muscles [1], fast-twitch rat EDL muscle [2] 
and 14-month-old rat EDL and mixed-fiber type muscles [12]. 
The ratio in transgenic skeletal muscles was 1.28 ±0.09. The 
significant increase in PN200-110/ryanodine binding ratio 
(P< 0.001) in transgenic muscles is caused by the increase 
in the number of DHPR. It has been shown that only a 
fraction of the RyRl is coupled to DHPR in fast-twitch ro-
dent muscles [1,2]. Results from the present study support the 
concept that the fraction of RyRl coupled to DHPR increases 
in transgenic mice. The increase in the maximum [3H]PN200-
110 binding capacity cannot be attributed to a decrease in the 
dissociation constant of [3H]PN200-110 (Table 1). 
3.1. DHPR and RyRl in EDL and soleus muscles 
To determine whether the increase in the number of DHPR 
in the pools of transgenic muscles was due to an increase in 
the number of DHPR in fast- and/or slow-twitch muscles, 
binding studies were performed in EDL or soleus muscles 
(Table 1). The 5 m a x values of DHPR and RyRl in EDL 
and soleus muscles were determined by a single saturating 
concentration of [3H]PN200-110 and [3H]ryanodine. The 
DHPR 5 m a x values for transgenic and non-transgenic muscles 
were 10.57 ±2.15 and 7.02 ±1.71 pmol/mg protein, respec-
tively, and for RyRl were 8.28 ±1.56 and 6.70 ±1.03 pmol/ 
mg protein, respectively. Transgenic EDL muscles exhibited a 
statistically significant increase in DHPR (P = 0.026); how-
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Fig. 2. [3H]PN200-110 (top) and [3H]ryanodine (bottom) binding to 
skeletal muscle homogenates in 12-month-old non-transgenic and 
transgenic mice. BmBX and Kv values were obtained from Scatchard 
analysis and fitting of Eq. 1 to binding data (inset). The plots corre-
spond to representative experiments of the total number of studies 
(10 determinations from five samples) included in Table 1. 
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ever, no significant differences in RyRl concentration were 
found (P = 0.095). The Bmí¡x values for DHPR and RyRl in 
non-transgenic EDL and soleus (see below) muscles are equiv-
alent to those reported in rat EDL muscle [12,14], when ex-
pressed per gram muscle. In our hands, 1 g of EDL or soleus 
muscles gave 100 ±30 mg protein («=10). The DHPR/RyRl 
Bmax ratio for non-transgenic skeletal muscle was 1.038 ± 0.12. 
This value is similar to 0.95 ±0.14 reported for rat EDL 
muscles [12]. In transgenic skeletal muscle DHPR/RyRl ratio 
increased significantly to 1.28 ±0.16 LP=0.027) due to the in-
crease in the amount of DHPR. 
Bmax values for DHPR in transgenic and non-transgenic 
soleus muscles were 5.17 ±0.71 and 3.04 ± 1.18 pmol/mg pro-
tein, respectively. For RyRl the values for both groups of 
muscles were 6.57 ± 1.50 and 6.43 ±0.79 pmol/mg protein, re-
spectively. The number of DHPR in transgenic soleus muscle 
was 70% higher than in non-transgenic (P = 0.008). However, 
no significant changes in the number of RyRl were detected 
(P = 0.858). The DHPR/RyRl ratio of 0.47 ±0.18 observed in 
non-transgenic soleus muscle is consistent with the value of 
0.44 ±0.12 seen in 14-month-old rat soleus muscle fiber [12]. 
This ratio increased to 0.80 ±0.12 in transgenic soleus muscle. 
The increase in DHPR/RyRl ratio is due to the increase in 
the number of DHPR. In summary, these results indicate that 
the increase in the number of DHPR and DHPR/RyRl ratio 
observed in mixed-fiber type muscles is due to the increase in 
the number of DHPR in both fast- and slow-twitch muscles. 
4. Discussion 
In the present work we report that transgenic overexpres-
sion of IGF-1 exclusively in skeletal muscle increases the num-
ber of DHPR a l subunit in adult mouse. The DHPR cxl 
subunit functions both as a voltage sensor and as a permea-
tion pathway for Ca2+ ions in skeletal muscles [15]. When 
muscles from S1S2 transgenic mice were compared with 
FVB non-transgenic mice, a significant increase in DHPR 
was evident. The levels of RyRl, which functions as the 
Ca2+ release channel in EC coupling [16], did not change 
significantly in transgenic compared to non-transgenic 
muscles. Because the DHPR/RyRl ratio increased 30% in 
transgenic compared to non-transgenic muscle, we postulate 
that the IGF-1-mediated increase in DHPR may overcome 
reported defects in EC coupling with aging [5,11,17]. 
IGF-1 plays a crucial role in skeletal muscle growth and 
maintenance [3]. Systemic transgenic overexpression of IGF-1 
has shown a modest improvement in muscle mass [18,19]. 
However, overexpression of IGF-1 targeted to striated 
muscles causes uniform muscle hypertrophy without increase 
in overall body weight or circulating IGF-1 concentration 
[19]. The mechanism of IGF-1 action in the signaling pathway 
has been extensively studied, however the mechanism of Ca2+ 
channel upregulation reported in this work is unknown. Be-
cause DHPR expression has been associated with skeletal 
muscle activity [14], it should be mentioned that both trans-
genic and non-transgenic mice were housed in similar cages 
and exhibited similar physical activity. IGF-1 is known to 
induce the transcription of the immediate-early genes c-fos 
and c-jun. Members of the Fos and Jun protein families di-
merize to form the AP-1 complex which binds to the TPA 
responsive element (TRE) present in the promoter of respon-
sive genes [20]. IGF-1 has been shown to stimulate c-fos and 
c-jun transcription in PC12 cells [21]. Transfection of PC12 
cells with c-fos and c-jun increased (O-conotoxin-sensitive cal-
cium current 2-4-fold in 2 days thereby suggesting that re-
newed induction of both c-fos and c-jun may be required for 
sustained enhancement of Ca2+ influx [22]. Kojima et al. have 
shown that IGF-1 stimulates Ca2+ influx by activating a 
Ca2+-permeable cation channel via the IGF-1 receptor and 
Ca2+ influx may play a critical role in the mitogenic action 
of IGF-1 [23]. Although the mechanism by which sustained 
overexpression of IGF-1 induces upregulation of DHP-sensi-
tive Ca2+ channels in skeletal muscle is unknown, based on 
observations in other cell types, it may occur via modulation 
of API or CRE sites. 
Acknowledgements: This work was supported by National Institutes 
of Health (NIA) Grants K01AG00692, R29AG13934 and 
P60AG10484 (O.D.). M.R. was supported by T-32-AG00182. We 
are very grateful to Dr. William E. Sonntag for helping us in RIA 
determinations of IGF-1 concentration in skeletal muscle. 
References 
[1] Anderson, K., Cohn, A.H. and Meissner, G. (1994) Am. J. Phys-
iol. 266, C462^166. 
[2] Delbono, O. and Meissner, G. (1996) J. Membr. Biol. 151, 123 
130. 
[3] Florini, J.R., Ewton, D.Z. and Coolican, S.A. (1996) Endocr. 
Rev. 17, 481-517. 
[4] Delbono, O., Renganathan, M. and Messi, M.L. (1997) J. Neuro-
sci. 17 (18), 6918-6928. 
[5] Renganathan, M., Sonntag, W.E. and Delbono, O. (1997) Bio-
chem. Biophys. Res. Commun. 235, 784-789. 
[6] Delbono, O., Renganathan, M. and Messi, M.L. (1997) Muscle 
Nerve (in press). 
[7] Coleman, M.E., DeMayo, F., Yin, K.C., Lee, H.M., Geske, R., 
Montgomery, C. and Schwartz, R.J. (1995) J. Biol. Chem. 270, 
12109-12116. 
[8] Brooks, S.V. and Faulkner, J.A. (1994) Am. J. Physiol. 267, 
C507-513. 
[9] Booth, F.W., Weeden, S.H. and Tseng, B.S. (1994) Med. Sei. 
Sports Exercise 26, 556-560. 
[10] Edstrom, L. and Larsson, L. (1987) J. Physiol. 392, 129-145. 
[11] Delbono, O., O'Rourke, K.S. and Ettinger, W.H. (1995) 
J. Membr. Biol. 148, 211-222. 
[12] Renganathan, M., Messi, M.L. and Delbono, O. (1997) 
J. Membr. Biol. (in press). 
[13] Sonntag, W.E., Steger, R.W., Forman, L.J. and Meites, J. (1980) 
Endocrinology 107, 1875-1879. 
[14] Saborido, A., Molano, F., Moro, G. and Megias, A. (1995) 
Pflugers Arch. Eur. J. Physiol. 429, 364-369. 
[15] Melzer, W., Herrmann-Frank, A. and Luttgau, H.C. (1995) Bio-
chim. Biophys. Acta 1241, 59-116. 
[16] Meissner, G (1994) Annu. Rev. Physiol. 56, 485-508. 
[17] Delbono, O.R., Renganathan, M. and Messi, M.L. (1997) 
Muscle Nerve (in press). 
[18] Mathews, L.S., Hammer, R.E., Behringer, R.R., D'Ercole, A.J., 
Bell, G.I., Brinster, R.L. and Palmiter, R.D. (1988) Endocrinol-
ogy 123, 2827-2833. 
[19] Behringer, R.R., Lewin, T.M., Quaife, C.J., Palmiter, R.D., Brin-
ster, R.L. and D'Ercole, A.J. (1990) Endocrinology 127, 1033-
1040. 
[20] Angel, P., Hattori, K., Smeal, T. and Karin, M. (1988) Cell 55, 
875-885. 
[21] Monnier, D., Boutillier, A.L., Giraud, P., Chiu, R., Aunis, D., 
Feltz, P., Zwiller, J. and Loeffler, J.P. (1994) Mol. Cell. Endo-
crinol. 104, 139-145. 
[22] Cavalie, A., Berninger, B., Haas, C.A., Garcia, D.E., Lindholm, 
D. and Lux, D. (1994) J. Physiol. 479, 11-27. 
[23] Kojima, I., Matsunaga, H., Kurokawa, K., Ogata, E. and Nishi-
moto, I. (1988) J. Biol. Chem. 263, 16561-16567. 
